The 20 linked references in paper K. Mukhin Yu., O. Pylaeva A., К. Мухин Ю., О. Пылаева А. (2017) “Юношеская миоклоническая эпилепсия: акцент на применение топирамата (обзор литературы и собственные данные) // JUVENILE MYOCLONIC EPILEPSY: FOCUS ON THE USE OF TOPIRAMATE (LITERATURE REVIEW AND OWN DATA)” / spz:neicon:rjdn:y:2017:i:2:p:8-20

  1. DOI: 10.1212/01.wnl.0000313148.34629.1d. 11. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 2003;4(11):2079–88.
  2. DOI: 10.1517/14656566.4.11.2079. 12. Biraben A., Allain H., Scarabin J.M. et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurolo
  3. DOI: 10.1016/j.ebcr.2016.09.006. 14. Camfield C.S., Camfield P.R. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study. Neurology 2009;73
  4. DOI: 10.1212/WNL.0b013e3181b9c86f. 15. Chowdhury A., Brodie M.J. Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate.
  5. DOI: 10.1016/j.eplepsyres.2015.11.012. 16. Crespel A., Gelisse P., Reed R.C. et al. Management of juvenile myoclonic epilepsy. Epilepsy Behav 2013;28(1):S81–6.
  6. DOI: 10.1016/j.yebeh.2013.01.001. 17. Crespel A., Genton P., Berramdane M. et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic
  7. DOI: 10.1212/01.wnl.0000174517.21383.36. 18. Crespel A., Velizarova R., Genton P. et al. Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate. Therapie 200
  8. DOI: 10.2515/therapie/2009033. 19. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classif
  9. DOI: 10.1111/j.0013-9580.2004.19704.x. 23. Genton P., Gelisse P., Thomas P. Juvenile myoclonic epilepsy today: current definition and limits. In: Juvenile myoclonic epilepsy: the Janz s
  10. DOI: 10.1111/epi.13702. 26. Glauser T., Ben-Menachem E., Bourgeois B. et al. The ILAE Subcommission on
  11. DOI: 10.1111/epi.12074. 27. Gomez-Ibañez A., McLachlan R.S., Mirsattari S.M. et al. Prognostic factors in patients with refractory idiopathic generalized epilepsy. Epilepsy
  12. DOI: 10.1016/j.eplepsyres.2017.01.011. 28. Grunewald R.A. Juvenile myoclonic epilepsy. In: Atlas of Epilepsies. Ed. by C.P. Panayiotopoulos. London: Springer, 2010. Pp.
  13. DOI: 10.1016/j.clinph.2015.11.048. 34. Johannesen K., Marini C., Pfeffer S. et al. Phenotypic spectrum of GABRA1: from generalized epilepsies to severe epileptic
  14. DOI: 10.1212/WNL.0000000000003087. 35. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90(1):21–3
  15. DOI: 10.1016/j.yebeh.2007.03.003. 37. Liu J., Wang L.N., Wang Y.P. Topiramate monotherapy for juvenile myoclonic epilepsy. Cochrane Database Syst Rev 2015;(12):CD010
  16. DOI: 10.1002/14651858.CD010008.pub2. 38. Loddenkemper T., Berg A.T. Terminology for seizures and epilepsies. In: Wyllie’s treatment of epilepsy. Principles and practice. 6t
  17. DOI: 10.1016/j.jocn.2012.10.020. 45. Perucca E. The spectrum of the new antiepileptic drugs. Acta Neurol Belg 1999;99(4):231–8. PMID: 10674140. 46. Privitera M.
  18. DOI: 10.1111/j.1528-1167.2006.00584.x. 48. So G.M., Thiele E.A., Sanger T. et al. Electroencephalogram and clinical focalities in juvenile myoclonic epilepsy. J. Child Neurol 1998;
  19. DOI: 10.1177/088307389801301103. 49. Thomas P., Genton P., Gelisse P. et al. Juvenile myoclonic epilepsy. In: Epileptic syndromes in infancy,
  20. DOI: 10.1016/j.seizure.2016.09.005. Поступила: 21.04.2017. Рецензирование: 12.05.2017. Принята в печать: 27.05.2017 Received: 21.04.2017. Reviewing: 12.05.2017.